Retatrutide-A Game Changer in Obesity Pharmacotherapy.

Retatrutide · PMID 40563436

Retatrutide's unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Retatrutide · PMID 37366315

We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.

Retatrutide · PMID 41090431

Emerging pharmacotherapies for obesity: A systematic review.

Retatrutide · PMID 39952695

The obesity drug pipeline is expanding rapidly, with the most promising results reported with incretin analogs.

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

Retatrutide · PMID 38843460

Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.

Retatrutide · PMID 39761578

Retatrutide (12 mg once weekly) produced greater weight loss of up to 22.1% (CI, 19.3% to 24.9%) after 48 weeks; other novel single and combination GLP-1 agents were also efficacious to varying degrees.